Ravi Vij, MD
Enriched profileJeffrey S. and Prue H. Gershman Distinguished Professor, Professor of Medicine, Division of Oncology · Washington University School of Medicine in St. Louis
Ravi Vij is Jeffrey S. and Prue H. Gershman Distinguished Professor, Professor of Medicine, Division of Oncology at Washington University School of Medicine in St. Louis. OpenAlex indexes 952 publications with 28,353 citations (h-index 76); ClinicalTrials.gov lists 26 registered studies with this person as an investigator.
Data verified 18 Oct 2026
Overview
Updated 18 Oct 2026
Ravi Vij, MD, is Jeffrey S. and Prue H. Gershman Distinguished Professor, Professor of Medicine, Division of Oncology at Washington University School of Medicine in St. Louis. The public record shows 952 publications with 28,353 citations (h-index 76), centered on Multiple Myeloma Research and Treatments, Chronic Lymphocytic Leukemia Research, Hematopoietic Stem Cell Transplantation. It also documents an investigator role on 26 registered clinical trials, industry payments reported by 32 companies.
- Most recent indexed publication: 2026 · British journal of haematology
- Top research focus: Multiple Myeloma Research and Treatments
- 26 registered trials on ClinicalTrials.gov
- Open Payments reporting from 32 companies
Generated from the cited public record · current as of 18 Oct 2026. Every fact links its source below.
Indications focus
from trials led + research topicsResearch focus
OpenAlex concept fingerprintDrugs & molecules
across trials, industry payments and publicationsWorks with
trial sponsors and companies reporting paymentsScholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID; 9 in PubMed.
Total citations across indexed works.
Hirsch index (OpenAlex). i10-index 340.
Clinical & industry
trials, payments and federal fundingFederally funded research awards.
Contact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
Telephone
Practice address and telephone from the federal NPPES registry.
Sign in to view contact details →Clinical trials
Updated 18 Oct 2026
Listed as an investigator on 26 registered studies on ClinicalTrials.gov. The most recent:
- Selinexor Maintenance Post CAR-T Cell Therapy for Multiple Myeloma
Sponsor: Washington University School of Medicine
- 64Cu-LLP2A for Imaging Hematologic Malignancies
Sponsor: Washington University School of Medicine
- Lymphodepleting Total Body Irradiation (TBI) Plus Cyclophosphamide Prior to Ciltacabtagene Autoleucel (Carvykti; Cilta-cel) for Multiple Myeloma (MM) Patients With Impaired Renal Function
Sponsor: Washington University School of Medicine
Industry payments
Updated 18 Oct 2026
32 companies reported payments to CMS in program years 2021–2025. These are public disclosures, not judgments. The latest:
- Janssen Biotech, Inc.Program year20257 payments
- PFIZER INC.Program year20252 payments
- GENZYME CORPORATIONProgram year20251 payment
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cancer & immunology
59.2%CD38-directed Cytolytic Antibody55.5%Daratumumab100%Part B, office-administered≥24 patientsThalidomide Analog3.3%Lenalidomide39%Pomalyst33%Revlimid28%Part D≥22 patients+ 2 more classes in this area
Metabolism & gastrointestinal
23.1%Other antiemetics18.3%Fosaprepitant100%Part B, office-administered≥13 patientsSerotonin-3 Receptor Antagonist3.7%Palonosetron hcl56%Granisetron hydrochloride37%Ondansetron Hcl4%Ondansetron Odt3%Part D + Part B<11 patients+ 5 more classes in this area
Sensory organs
7.8%Corticosteroid7.8%Dexamethasone sodium phosphate86%Dexamethasone14%Part D + Part B≥40 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
We didn't find any NIH-funded research awards for this person in NIH RePORTER. Why? →
Congress activity
Updated 18 Oct 2026
184 congress contributions (2004–2026) across AACR, ASCO, ASH, ASTRO per OpenAlex. The most recent:
- Abstract 2261: Distinct genomic and high-risk cytogenetic features in black multiple myeloma patients: Insights from the PE-CGS Network
AACR Annual Meeting
AACR2025Co-author
Published abstracts are attributed via the same ORCID-disambiguated authorship as publications, so each is DOI-verified. Podium roles (invited talks, session chairs) and oral/poster type are added as program data is confirmed.
Publications
Updated 18 Oct 2026
Their five most recent publications, matched to their ORCID record and linked to PubMed.
- The association between allostatic load and monoclonal gammopathy of undetermined significance (MGUS).
British journal of haematology
Article2026 - High-Deductible Health Plans and Out-of-Pocket Health Care Costs Among Younger Patients With Multiple Myeloma.
JCO oncology practice
Article2026 - Mixed-Methods Study on the Responsiveness of the Comprehensive Score for Financial Toxicity Among People With Multiple Myeloma.
JCO oncology practice
Article2024 - Single-Cell Discovery and Multiomic Characterization of Therapeutic Targets in Multiple Myeloma.
Cancer research
Article2023
Most-cited works
by citation count (OpenAlex)- 01Initial genome sequencing and analysis of multiple myelomaArticle1,435 citations2011
- 02Lenalidomide after Stem-Cell Transplantation for Multiple MyelomaArticle1,151 citations2012
- 03Widespread Genetic Heterogeneity in Multiple Myeloma: Implications for Targeted TherapyArticle986 citations2014
- 04TP53 and Decitabine in Acute Myeloid Leukemia and Myelodysplastic SyndromesArticle791 citations2016
- 05Ide-cel or Standard Regimens in Relapsed and Refractory Multiple MyelomaArticle776 citations2023
Network
Updated 18 Oct 2026
The people this person publishes with most, by number of co-authored papers. Names link to their own profile when we have one.
Online presence
Updated 18 Oct 2026
This person's own public accounts first, then places where others mention them. Two different things, listed separately.
Mentions by others
where others cite or feature them- Other
oncology.wustl.edu
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →oncology.wustl.edu ↗ - Other
physicians.wustl.edu/people/ravi-vij-md
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →physicians.wustl.edu ↗
We list an account only when the public record ties it to this person. verified means we've confirmed the match in more than one place; provisional means it looks right but we're still confirming.
Background & recognition
Updated 18 Oct 2026
Credentials, appointments and honors, newest first, each linked to the public source it came from.
Education
degrees and training on record- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →oncology.wustl.edu ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →oncology.wustl.edu ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →oncology.wustl.edu ↗
Editorial & leadership roles
journal and society appointments- Senior Editor
Clinical Lymphoma, Myeloma and Leukemia
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →oncology.wustl.edu ↗ - Chair
ASH Scientific Committee on Plasma Cell Dyscrasias
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →oncology.wustl.edu ↗ - Member
CALGB/Alliance Core Transplant, Myeloma and Leukemia Committees
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →oncology.wustl.edu ↗ - Member
Myeloma Committee, BMT Clinical Trials Network
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →oncology.wustl.edu ↗ - Member
Multiple Myeloma Cancer Immunotherapy Guideline Panel
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →oncology.wustl.edu ↗ - Member
ASCO Education and Scientific Committees
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →oncology.wustl.edu ↗
Awards & honors
honors on the public record- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →source.washu.edu ↗
- provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →healthtree.org ↗
- provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →healthtree.org ↗
- provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →healthtree.org ↗
Secondary affiliations
appointments beyond the home institution- Siteman Cancer Center
Medical Director
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →oncology.wustl.edu ↗ - verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →profiles.wustl.edu ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →profiles.wustl.edu ↗
Media & interviews
press, podcasts and appearances- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →healthtree.org ↗
- HealthTree Podcast Speaker - Multiple Myeloma Topics including CAR-T cells
clinical trials, and relapsed/refractory myeloma
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →healthtree.org ↗ - Speaker
Advancing Myeloma Care: Current Clinical Trials and Research at Siteman Cancer Center
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →healthtree.org ↗
Every item links to where we found it. verified means we've confirmed it in more than one place; provisional means we found it and are still confirming.
Similar KOLs
Other experts from the same institution or the same specialty.
Ramaswamy Govindan, MD
Washington University School of Medicine in St. Louis
Marin Kollef, MD
Washington University School of Medicine in St. Louis
Mark Huffman, MD
Washington University School of Medicine in St. Louis
Brad Kahl, MD
Washington University School of Medicine in St. Louis
Kenneth Anderson, MD
Dana-Farber Cancer Institute
Paul Richardson, MD
Dana-Farber Cancer Institute
S Rajkumar, MD
Mayo Clinic
Meletios Dimopoulos, MD
National and Kapodistrian University of Athens